Miltefosine
Therapeutic Group
Anti-neoplasticsIndication Dosage
Miltefosine is a medication indicated for the treatment of visceral leishmaniasis (kala-azar) in pediatric and adult patients. This oral medication is specifically approved for use in regions where the disease is endemic and caused by Leishmania donovani or Leishmania infantum parasites. It serves as a valuable therapeutic option in the management of this potentially life-threatening parasitic infection.
Visceral Leishmaniasis, Adjunct Therapy In Colorectal Cancer And Metastatic Breast Cancer:
- Adults: 50-150 Mg Daily For 28 Days.
Content
- Cap: Miltefosine 50mg.
Pregnancy
Contraindicated In Pregnancy.
Stability
- Phospholipid Derivative
Contra Indications
- None Known
Precautions
- None Known
Lactation
- Contraindicated. Discontinue Breast-feeding
Side Effects
- Hepatotoxicity
- Liver Damage
- Diarrhoea
- Nausea
- Vomiting
- Oral Mucositis